Should I buy or sell TELA Bio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TELA Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TELA shares. View TELA analyst ratings or view top-rated stocks .

What is TELA Bio's stock price target for 2024?

2 Wall Street research analysts have issued 12 month price targets for TELA Bio's shares. Their TELA share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 202.4% from the stock's current price. View analysts price targets for TELA or view top-rated stocks among Wall Street analysts .

How have TELA shares performed in 2023?

TELA Bio's stock was trading at $11.50 on January 1st, 2023. Since then, TELA shares have decreased by 56.9% and is now trading at $4.96. View the best growth stocks for 2023 here .

When is TELA Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024. View our TELA earnings forecast .

How were TELA Bio's earnings last quarter?

TELA Bio, Inc. (NASDAQ:TELA) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.05. The firm earned $7.65 million during the quarter, compared to the consensus estimate of $7.30 million. TELA Bio had a negative net margin of 82.43% and a negative trailing twelve-month return on equity of 198.87%.

What other stocks do shareholders of TELA Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TELA Bio investors own include Micron Technology (MU) , Intel (INTC) , Pfizer (PFE) , CrowdStrike (CRWD) , Walt Disney (DIS) , Gilead Sciences (GILD) , Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Alteryx (AYX) and Cisco Systems (CSCO) .

When did TELA Bio IPO?

(TELA) raised $60 million in an initial public offering on Friday, November 8th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are TELA Bio's major shareholders?

TELA Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (5.12%), Pentwater Capital Management LP (3.78%), Federated Hermes Inc. (2.91%), Sectoral Asset Management Inc. (2.14%), Stonepine Capital Management LLC (2.01%) and Silverarc Capital Management LLC (2.00%). Insiders that own company stock include Antony Koblish, Ew Healthcare Partners Fund 2-, Ew Healthcare Partners Fund 2,, Opaleye Management Inc, Orbimed Advisors Llc and Roberto Cuca . View institutional ownership trends .

How do I buy shares of TELA Bio?

Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

TELA Bio Stock Price, News & Analysis (NASDAQ:TELA)

$4.96

+0.10 (+2.06%)

(As of 11/29/2023 ET)

Compare

Today's Range: $4.87
▼
$5.03
50-Day Range: $4.50
▼
$8.20
52-Week Range: $4.23
▼
$13.18

Volume: 162,129 shs
Average Volume: 232,737 shs
Market Capitalization: $121.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

TELA Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 202.4% Upside
$15.00 Price Target
Short Interest: Healthy
2.95% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$94,840 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.96) to ($1.51) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

294th out of 949 stocks

Surgical & Medical Instruments Industry

39th out of 96 stocks

3.5

Analyst's Opinion

Consensus Rating
TELA Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, TELA Bio has a forecasted upside of 202.4% from its current price of $4.96.
Amount of Analyst Coverage
TELA Bio has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.95% of the outstanding shares of TELA Bio have been sold short.
Short Interest Ratio / Days to Cover
TELA Bio has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in TELA Bio has recently decreased by 1.81%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
TELA Bio does not currently pay a dividend.
Dividend Growth
TELA Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TELA.

2.7

News and Social Media Coverage

News Sentiment
TELA Bio has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for TELA Bio this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TELA Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $94,840.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.70% of the stock of TELA Bio is held by insiders.
Percentage Held by Institutions
91.06% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for TELA Bio are expected to grow in the coming year, from ($1.96) to ($1.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TELA Bio is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TELA Bio is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TELA Bio has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About TELA Bio Stock (NASDAQ:TELA)

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TELA Stock News Headlines

November 16, 2023 | finance.yahoo.com

TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference

November 13, 2023 | msn.com

TELA Bio files for $150M mixed shelf

November 30, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 12, 2023 | finance.yahoo.com

TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript

November 10, 2023 | morningstar.com

TELA Bio Inc Ordinary Shares TELA

November 10, 2023 | finanznachrichten.de

TELA Bio, Inc.: TELA Bio Reports Third Quarter 2023 Financial Results

November 10, 2023 | markets.businessinsider.com

Buy Rating for TELA Bio: Resilience and Growth Potential despite Challenges

November 10, 2023 | msn.com

TELA Bio GAAP EPS of -$0.45 misses by $0.29, revenue of $15.1M misses by $1.1M

November 30, 2023 | Tomorrow Investor (Ad)

Why Microsoft Just Placed A Huge Bet On Nuclear

Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.

October 26, 2023 | finance.yahoo.com

TELA Bio to Announce Third Quarter 2023 Financial Results

September 21, 2023 | finance.yahoo.com

Opaleye Management Inc. Reduces Stake in Harrow Health Inc.

September 18, 2023 | finance.yahoo.com

TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase

August 18, 2023 | bizjournals.com

Lab Notes: Tela Bio launches new product; Amicus gets approval for its Pompe disease treatment in UK

August 17, 2023 | msn.com

TELA Bio rolls out new OviTex resorbable for implantation

August 16, 2023 | finance.yahoo.com

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

August 11, 2023 | finanznachrichten.de

TELA Bio, Inc.: TELA Bio Reports Second Quarter 2023 Financial Results

August 11, 2023 | finance.yahoo.com

TELA Bio, Inc. (NASDAQ:TELA) Q2 2023 Earnings Call Transcript

August 10, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on TELA Bio (TELA)

August 10, 2023 | finance.yahoo.com

Q2 2023 TELA Bio Inc Earnings Call

August 10, 2023 | finance.yahoo.com

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

August 9, 2023 | msn.com

AMMO Non-GAAP EPS of $0.05 beats by $0.03, revenue of $34.25M misses by $4.57M

August 9, 2023 | finance.yahoo.com

TELA Bio Reports Second Quarter 2023 Financial Results

August 5, 2023 | finanznachrichten.de

TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 27, 2023 | finance.yahoo.com

TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

July 6, 2023 | finance.yahoo.com

Roivant Sciences Ltd. (ROIV) Surges 8.9%: Is This an Indication of Further Gains?

June 21, 2023 | msn.com

TELA Bio: Turning More Constructive

June 19, 2023 | finance.yahoo.com

Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength?

See More Headlines

Receive TELA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TELA Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TELA
CUSIP: N/A
CIK: 1561921
Web: www.telabio.com
Phone: 484-320-2930
Fax: N/A
Employees: 173
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $15.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +202.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,300,000.00
Net Margins: -82.43%
Pretax Margin: -82.43%
Return on Equity: -198.87%
Return on Assets: -56.76%

Debt

Debt-to-Equity Ratio: 1.32
Current Ratio: 5.36
Quick Ratio: 4.43

Sales & Book Value

Annual Sales: $41.42 million
Price / Sales: 2.93
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.25 per share
Price / Book: 3.97

Miscellaneous

Outstanding Shares: 24,490,000
Free Float: 23,093,000
Market Cap: $121.47 million
Optionable: Not Optionable
Beta: 1.03

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Antony Koblish (Age 57)
Co-founder, President, CEO & Director
Comp: $967.67k
Mr. Roberto E. Cuca J.D. (Age 55)
CFO & COO
Comp: $643.37k
Mr. Paul Talmo
Chief Strategic Officer
Ms. Megan Smeykal (Age 47)
VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer
Dr. E. Skott Greenhalgh Ph.D. (Age 55)
Chief Technology Officer
Comp: $534.67k
Mr. D. Taylor Ocasio
General Counsel & Corporate Secretary
Mr. Christopher H. Smith (Age 62)
Senior Vice President of Sales
Ms. Jennifer Lou Armstrong (Age 53)
Senior Vice President of Human Resources
Mr. Gregory A. Firestone
Chief Business Officer
Mr. Michael Leonard
Senior Vice President of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TELA Stock Analysis - Frequently Asked Questions

Should I buy or sell TELA Bio stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TELA Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TELA shares.
View TELA analyst ratings or view top-rated stocks.
What is TELA Bio's stock price target for 2024?: 2 Wall Street research analysts have issued 12 month price targets for TELA Bio's shares. Their TELA share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 202.4% from the stock's current price.
View analysts price targets for TELA or view top-rated stocks among Wall Street analysts.
How have TELA shares performed in 2023?: TELA Bio's stock was trading at $11.50 on January 1st, 2023. Since then, TELA shares have decreased by 56.9% and is now trading at $4.96.
View the best growth stocks for 2023 here.
When is TELA Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024.
View our TELA earnings forecast.
How were TELA Bio's earnings last quarter?: TELA Bio, Inc. (NASDAQ:TELA) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.05. The firm earned $7.65 million during the quarter, compared to the consensus estimate of $7.30 million. TELA Bio had a negative net margin of 82.43% and a negative trailing twelve-month return on equity of 198.87%.

What other stocks do shareholders of TELA Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TELA Bio investors own include Micron Technology (MU), Intel (INTC), Pfizer (PFE), CrowdStrike (CRWD), Walt Disney (DIS), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Alteryx (AYX) and Cisco Systems (CSCO).
When did TELA Bio IPO?: (TELA) raised $60 million in an initial public offering on Friday, November 8th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Who are TELA Bio's major shareholders?: TELA Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (5.12%), Pentwater Capital Management LP (3.78%), Federated Hermes Inc. (2.91%), Sectoral Asset Management Inc. (2.14%), Stonepine Capital Management LLC (2.01%) and Silverarc Capital Management LLC (2.00%). Insiders that own company stock include Antony Koblish, Ew Healthcare Partners Fund 2-, Ew Healthcare Partners Fund 2,, Opaleye Management Inc, Orbimed Advisors Llc and Roberto Cuca.
View institutional ownership trends.
How do I buy shares of TELA Bio?: Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TELA) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial